





New Mexico HPV Pap Registry NMHPVPR



**A partnership of
local, national and
federal
organizations,
agencies and
content experts**





Current Reporting New Mexico Laboratory State-wide Distribution

~610,000 women base
Reporting is 99% EMR,
95% all NM residents screening

Includes labs outside of NM
representing <20% of all tests

National Labs

Quest

Ameripath

Labcorp


ARUP

Texas Labs


CDD

Cytolabs

Mattison



New Mexico HPV Pap Registry Data Flow Diagram



WHEREAS the UNM HSC has been established by the Legislature of the State of New Mexico, Chapter 100, Section 1-10, NMSA 1978, as amended;

NOW THEREFORE:

The NM-DOH and UNM-HE



owing:

1. The UNM-HSC shall have the authority to perform the functions of the NM-DOH authorized by the Legislature of the State of New Mexico, Chapter 100, Section 1-10, NMSA 1978, as amended, and to exercise the powers of the NM-DOH as provided in the Health Care Code, Chapter 71, NMSA 1978, as amended, and to exercise the powers of the NM-DOH as provided in the Health Care Code, Chapter 71, NMSA 1978, as amended.

2. The New Mexico HSC shall have the authority to perform the functions of the NM-DOH authorized by the Legislature of the State of New Mexico, Chapter 100, Section 1-10, NMSA 1978, as amended, and to exercise the powers of the NM-DOH as provided in the Health Care Code, Chapter 71, NMSA 1978, as amended, and to exercise the powers of the NM-DOH as provided in the Health Care Code, Chapter 71, NMSA 1978, as amended.

g Committee

3. The NMHPVHR is governed as outlined in Appendix 1 by an expert Scientific



HPV by Age

**Number of Days Between Pap and Biopsy All
New Mexico Labs by Cytologic Diagnosis
Pap Test in 2006, Biopsies through 2007**

HPV Viral Ecology Surveillance Research Component



HPV Genotyping Study

New Mexico State-Wide Population Baseline

		<i>Total Pap Tests¹</i>	<i>In Study Labs²</i>	<i>Specimens Selected³</i>	<i>Specimens Located⁴</i>	<i>HPV Genotyping⁵</i>
<i>Age</i>	<i>Pap Diagnosis</i>	<i>N</i>	<i>N (%)</i>	<i>N (%)</i>	<i>N (%)</i>	<i>N (%)</i>
<i><=30</i>	<i>Abnormal</i>	17785	13769 (77%)	13668 (77%)	12397 (70%)	10881 (61%)
	<i>Normal</i>	109449	79568 (73%)	37571 (34%)	34422 (31%)	29037 (27%)
<i>> 30</i>	<i>Abnormal</i>	13298	11144 (84%)	11063 (83%)	9865 (74%)	8644 (65%)
	<i>Normal</i>	216634	177240 (82%)	13242 (6%)		

- enabling comparative effectiveness of US cervical screening and HPV vaccination
 - and impact of interventions vs. guidelines and “expected”
 -

